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promising potential as antiviral and anti-inﬂammatory agents.
To deliver siRNA across cell membranes to reach the RNAi
pathway in the cytosol of target cells, non-viral nanoparticulate
delivery approaches are explored. Recently, we showed that
encapsulation of siRNA in lipid-polymer hybrid nanoparticles
(LPNs), based on poly(DL-lactic-co-glycolic acid) (PLGA) and
cationic lipid-like materials (lipidoids), remarkably enhances
intracellular delivery of siRNA as compared to siRNA delivery
with LPNsmodiﬁed with dioleoyltrimethylammoniumpropane
(DOTAP) as the lipid component. However, the potential im-
mune modulation by these cationic lipids remains unexplored.
By testing lipidoids and DOTAP for innate immune-receptor-
activating properties in vitro, we found that neither lipidoids
nor DOTAP activate human Toll-like receptor (TLR) 2, 3, 7,
and 9. However, in contrast to DOTAP, lipidoids are strong
agonists for TLR4 and activate murine antigen-presenting cells
in vitro. This agonistic effect was further conﬁrmed in silico
using a prediction model based on crystal structures. Also, lip-
idoids formulated as lipoplexes or as stable nucleic acid lipid
particles, which was the reference formulation for siRNA deliv-
ery, proved to activate TLR4. However, by combining lipidoids
with PLGA into LPNs, TLR4 activation was abrogated. Thus,
lipidoid-mediated TLR4 activation during siRNA delivery
may be modulated via optimization of the formulation design.
INTRODUCTION
Small interfering RNA (siRNA) holds a highly promising therapeutic
potential for the treatment of a variety of diseases via gene silencing.1–3
However, the physicochemical properties of siRNA often limit its
therapeutic efﬁcacy, rendering it unfavorable for efﬁcient intracellular
delivery to the RNAi pathway mediating gene silencing in the cytosol
of the target cells. These properties include a relatively large molecular
weight and high hydrophilicity as a result of the polyanionic phos-
phate backbone, leading to negligible cellular membrane permeation.
Therefore, realization of the therapeutic potential of siRNA is fullyMolecular T
This is an open access article under tdependent on the design and development of efﬁcacious and safe
siRNA delivery technologies.
Intracellular delivery of siRNA can be enhanced by employing nano-
particle-based delivery approaches.4–7 Lipid-based delivery systems,
in particular cationic lipids, have been shown to facilitate overcoming
the critical obstacles to efﬁcient siRNA delivery, which include phar-
macokinetic barriers (a short circulation half-life due to susceptibility
for nuclease degradation) and barriers at the cellular level (cellular
uptake, intracellular trafﬁcking, and endosomal escape to reach the
cytosol).5 However, major drawbacks of commonly applied cationic
lipids for siRNA delivery, e.g., 1,2-dioleoyl-3-trimethylammonium-
propane (DOTAP), 1,2-di-O-octadecenyl-3-trimethylammonium
propane (DOTMA), and dimethyldioctadecyl-ammonium bromide
(DDAB), include (1) limited electrostatic interaction with siRNA as
a result of the single quaternary ammonium head group (as opposed
to structures containing multiple amine functionalities; see below),
(2) activation of the innate immune system leading to undesired
side effects, and (3) unfavorable biodistribution because of nonspe-
ciﬁc tissue distribution and protein binding, eventually resulting in
a relatively narrow therapeutic window.8,9
Recent advances in the ﬁeld of RNAi therapeutics have led to the
identiﬁcation of a novel class of synthetic cationic lipids, the so-called
lipidoids, which are capable of mediating highly efﬁcient intracellular
delivery of siRNA.10–14 Lipidoids are lipid-like structures containing
multiple secondary and tertiary amine functionalities, which conferherapy: Nucleic Acids Vol. 11 June 2018 ª 2018 The Authors. 159
he CC BY license (http://creativecommons.org/licenses/by/4.0/).
Molecular Therapy: Nucleic Acidshighly efﬁcient interaction with anionic siRNAmolecules.10 Lipidoids
have been formulated as long-circulating stable nucleic acid lipid
particles (SNALPs), also containing cholesterol and PEGylated
phospholipids, for intravenous administration.10,15 The therapeutic
efﬁcacy of lipidoid-based SNALPs has been demonstrated in a number
of in vivo models, but data from these studies also indicate potential
symptoms of splenomegaly at higher doses.10 In addition, lipidoids,
even in combination with control siRNA, can induce immunostimu-
latory effects.16 Several clinical trials involving SNALPs have been
terminated owing to the occurrence of an inﬂuenza-like syndrome
in the dosed patients.17–19 Premedication with corticosteroids is often
necessary to circumvent such infusion-related problems.20,21 Hence,
there is an urgent need for the design and development of novel and
safe drug delivery systems that circumvent the hurdles involved in
intracellular delivery of siRNA. Recently, we recognized the potential
of one speciﬁc type of nanocarrier, i.e., lipidoid-polymer hybrid
nanoparticles (LPNs), for which highly promising results were
demonstrated with respect to safe and efﬁcient intracellular delivery
of siRNA in vitro. These siRNA-loaded LPNs are composed of lipi-
doids and poly(DL-lactic-co-glycolic acid) (PLGA), and we recently
reported highly systematic optimization of their critical quality attri-
butes using a quality-by-design approach.22
Whereas gene silencing efﬁciency and effect on cell viability are often
reported in the literature, the immune modulatory effects of siRNA
and delivery systems remain poorly described. Potential immune
modulatory effects are essential to investigate and identify already
in the formulation development phase, and in vitro immunogenicity
studies constitute an important technology platform in the early
immunogenicity risk assessment of new formulations. Nucleic acids
generally activate the innate immune system via binding to pattern-
recognition receptors (PRRs), e.g., the Toll-like receptors (TLRs).23
Chemical modiﬁcation of siRNA is commonly used to reduce unde-
sired immune effects.24 However, functional excipients used for the
siRNA delivery systems may also be recognized by the immune sys-
tem because they adopt a structure similar to components of patho-
gens and hence stimulate a cascade of deleterious immune effects,
which may lead to failure of therapy.25 So far, immunogenicity
assessment of lipidoids has not been reported, albeit a thorough
evaluation is warranted, considering their promising therapeutic
potential.
The purpose of the present study was to assess the ﬁrst-line in vitro
immune modulatory effects of our previously synthesized and puri-
ﬁed array of lipidoid compounds22 by using human TLR reporter
cell-line-based assays and in silico modeling. These compounds
have a tetra-amine backbone and comprise different degrees of alkyl-
ation: the tetra-acylated lipidoid (L4) consists of an acylated backbone
displaying four acyl chains (isomeric mixture), the penta-acylated lip-
idoid (L5) carries an additional acyl chain (isomeric mixture), and the
hexa-acylated lipidoid (L6) is fully acylated (Figure S1 depicts the
most abundant isomers). We also tested a mixture of lipidoids with
different degrees of alkylation, which constitutes the end product of
the chemical synthesis reaction before puriﬁcation,22 referred to as160 Molecular Therapy: Nucleic Acids Vol. 11 June 2018lipidoid mix (Lmix). Furthermore, the immune modulatory effects
of LPNs containing the different types of lipidoids (L4, L5, L6,
and Lmix, respectively) were compared to those of lipoplexes, SNALPs,
and DOTAP-modiﬁed LPNs.
RESULTS
Bulk Lipidoids Activate TLR4 Responses
The potential immunogenicity of lipidoids reported previously10 was
evaluated by assessing the ability of the bulk compounds to activate
the innate immune system via TLRs by using human TLR reporter
cell lines. The lipidoids were tested for their ability to activate TLR2
using a reporter cell line expressing TLR2. No activation was noted
upon incubation with L5, even at the highest tested concentration
(10 mg/mL), whereas the positive control Pam3CSK4 activated TLR2
(Figure 1A). However, all lipidoids at concentrations above 1 mM
did interfere with TLR2 activation, as demonstrated in the presence
of the activator Pam3CSK4 (Figure 1B). The activity of L5 was further
tested against TLR3, and no activation was noted (Figure 1C). The ac-
tivity of L5 was further tested against TLR7 and TLR9, but no activa-
tion was measured either (data not shown).
In contrast, a concentration-dependent increase in the activation of
TLR4 was noted for all lipidoids, i.e., L4, L5, L6, and Lmix up to
1 mM concentrations (Figure 1D). No signiﬁcant difference in the
activation of TLR4 was noted between L4 and L5 at the highest tested
concentration (p value > 0.05). Overall, a statistically signiﬁcant
higher TLR4 activation was noted for L6 (p value < 0.001) and Lmix
(p value < 0.01) as compared to L5, for which reason L5 was selected
for further testing (Figures 1E and 1F). In contrast to L4–L6, DOTAP
did not activate TLR4 in the tested concentration range up to
28.6 mM, although TLR4 activation was noted at the highest tested
concentration of DOTAP (0.29 mM; p value < 0.01; Figure 1E). In or-
der to test for potential assay interference, the experiments were also
performed in the presence of the TLR4 agonist lipopolysaccharide
(LPS). At higher concentrations, both L5 and DOTAP inhibited
LPS-induced TLR4 activation (Figure 1F). This could be attributed
to multiple factors, including loss of cell viability and/or lipidoid to
ligand binding. Interference with the assay is a likely explanation
for the reduced TLR4 activation observed at high L5 concentrations
(above 1–10 mM lipidoid). Of note, at these high concentrations,
the strongest TLR4 activation was noted for L6, which showed the
least interference. Thus, the differences in TLR4 activating activity
between L4, L5, and L6 at high concentrations could be explained by
differential interference of the compounds with the assay. Thus,
L4, L5, and L6 (at concentrations above 0.1 mM), but not DOTAP
(up to 100 mM), activate TLR4, and interference with activation
occurs at higher concentrations for all lipidoids tested.
In Silico Prediction of Docking to TLR4/MD-2 Suggests that
Lipidoids Are Potent Agonists
Lipidoids have been designed for optimal RNAi experiments. Their
cationic head groups neutralize the anionic charges of the nucleic
acids that they transport, whereas their hydrophobic moieties provide
a scaffold for membrane fusion. These features also seem to induce
Figure 1. Lipidoid-Induced TLR Activation Assessed Using HEKblue Human TLR Reporter Cell Lines
(A) Incubation of the TLR2-expressing cell line for 16 hr at 37Cwith L5 and the positive control PAM3CSK4. (B) Incubation of the TLR2-expressing cell line with L4, L5, L6, and
Lmix in the presence of PAM3CSK4, 100 ng/mL, is shown. (C) Incubation of the TLR3-expressing cell line with L5 and positive control poly(I:C) is shown. (D and E) TLR4-
expressing cells were stimulated with L4, L5, L6, and Lmix concentrations ranging from 0.001 to 10 mM (D), as well as with L5 or DOTAP in the concentration range from 0.01 to
300 mM (E). (F) Activation of the TLR4-expressing cell line by L5 and DOTAP, respectively, in the presence of LPS, 10 ng/mL, is shown. Data have been corrected for
background measured for solvent-stimulated cells and are shown relative to the maximal response (100%) with the respective selective agonists: PAM3CSK4 (100 ng/mL for
TLR2; A and B), poly(I:C) (5 mg/mL for TLR3; C), and LPS (10 ng/mL for TLR4; D–F). Data represent mean values ± SD (n = 3; technical replicates) and represent results of one
of two independent experiments. Statistically significant differences from L5 are marked with x and from solvent are marked with y: **p < 0.01 and ***p < 0.001.
www.moleculartherapy.orginteractions with the innate immune LPS sensor TLR4/MD-2. TLR4
is associated with myeloid differentiation factor 2 (MD-2) on the cell
surface, andMD-2 is required for signaling.26 Whereas the number of
acyl chains and the presence of phosphate groups are known key fea-
tures for LPS recognition, we here explored the potential binding
mode of the positively charged lipidoids containing tetra-amine back-
bones. We will refer to the head group amines as N1, N2, N3, and N4
in the following section. At pH 7.0, L4 is predicted to possess proton-
ated head group amines in positions N1 and N3. Upon acidiﬁcation,
an additional protonation may take place on N4. The protonation
state differs slightly in L5, wherein the presence of an extra acyl chain
shifts the protonations to positions N2 and N4 at pH 7.0 and to N1,
N2, and N4 under more acidic conditions (pH 6.0). In contrast, pro-
tonation is predicted to take place on the N1 and N4 amines at bothpH 6.0 and pH 7.0, respectively, in case of L6. More acidic environ-
ments of pH 5.0 and below may trigger a third protonation at N2.
The experimentally observed interaction of lipidoids with the TLR4
reporter cell line was further investigated by in silico docking studies.
Docking was performed at pH 7.0 to compare binding afﬁnities to
MD-2 and TLR4 (Table 1) and to identify the binding modes for
lipidoids (Tables S1, S2, and S3) using Autodock Vina software.27
DOTAP and other ligand complexes with known crystal structures
were included as controls. These comprise of species-speciﬁc antago-
nist lipid Iva,28 the potent agonist lipid A of LPS from Escherichia
coli,29 and the potent antagonist eritoran.30
The predicted binding energies suggest that lipidoids are notably
more potent than other known TLR4 agonists, with a predictedMolecular Therapy: Nucleic Acids Vol. 11 June 2018 161
Table 1. Predicted Binding Energies for Compounds to Human TLR4/MD-2
(at pH 7.0)
Ligand
Active hTLR4/MD-2
(3FXI)
Active hMD-2
(3FXI)
Inactive hMD-2
(2E59)
L4 32.7 31.1 23.6
L5 39.2 36.5 33.2
L6 41.4 38.3 25.7
DOTAP 22.6 22.3 11.1
Lipid IVaa ND 18.5b 25.1
E. coli lipid Aa 34.7 27.7 ND
Eritorana ND 15.6b 23.3
Values are given in kcal/mol. The binding energies to active hMD-2 are extrapolated
from rigid docking of the ligand conformation observed in the crystal structures,
2E59 and 1Z65, respectively. ND, not determined.
aBinding energies are given for rigid docking to match the ligand conformations
observed in the crystal structures.
bLipid IVA and eritoran are antagonists.
Molecular Therapy: Nucleic Acidsbinding energy of 32.7 kcal/mol for L4, 39.2 kcal/mol for L5, and
41.4 kcal/mol for L6, whereas a much lower binding energy was pre-
dicted for DOTAP (22.6 kcal/mol; Table 1). The binding toMD-2 in
inactive28 and active conformations,29 respectively, was also
compared. For all crystal structures published to date, agonists
seem to interact with the F126 loop ofMD-2 that subsequently adopts
a more compact conformation, enabling TLR4 dimerization.29 In
contrast, in the absence of ligand or in the presence of an antagonist,
this loop protrudes into the solvent, which prevents receptor dimer-
ization, either directly by causing steric hindrance, or indirectly by not
contributing to the dimerization interface.30 Hence, the predicted
binding of L5 to active and inactive MD-2, respectively, was
compared: the afﬁnity was highest for the active MD-2 (36.5 kcal/
mol, as compared to33.2 kcal/mol for inactiveMD-2). The opposite
was the case for lipid IVa, which is a known antagonist in humans: the
afﬁnity for the inactive conformation ofMD-2 was25.1 kcal/mol, as
compared to 18.5 kcal/mol for the active MD-2. The afﬁnity of
DOTAP for inactive MD-2 was remarkably low (11.1 kcal/mol),
which suggests that the binding is probably not speciﬁc. Hence,
data support that L5 is likely to bind and activate TLR4/MD-2,
whereas DOTAP binding remains questionable. Interestingly, other
tested lipidoids (L4 and L6) also exhibited similar proﬁles for binding
energies to active and inactive TLR4/MD-2 (Table 1). Although, the
difference in the predicted binding energies was relatively higher
in case of L4 and L6, primary emphasis was given to L5 because of
its relatively higher transfection potential.22
Further, although E. coli LPS is the most potent TLR4/MD-2 agonist,
its lipid A moiety is predicted to bind with afﬁnities comparable but
lower than L5, which range from 27.7 kcal/mol for active MD-2 to
34.7 kcal/mol for the TLR4/MD-2 dimeric complex. This suggests
that core sugars contribute to the activity of LPS. Tetra-acylated
eritoran in contrast lacks sugars and resembles lipid IVa in terms of
binding energies (23.3 and 25.1 kcal/mol, respectively; Table 1).
As for LPS, L5 binds in the hydrophobic cleft of MD-2, where it makes162 Molecular Therapy: Nucleic Acids Vol. 11 June 2018extensive contacts both withMD-2 and the TLR4 dimer (referred to as
TLR4’; Figure 2A). The lack of direct interaction with TLR4 at the pri-
mary binding site is not uncommon and has also been described for
neoseptin, which is another unconventional ligand.31 L5 is buried
deeply in the MD-2 pocket (Figure 2B), where it is located much
deeper than lipid IVa (Figure 2C), which is an antagonist in humans.28
Its positioning is partially overlapping the binding region described for
a neoseptin dimer bound to mouse TLR4/MD-2.31 L5 is much larger
than the neoseptin dimer and makes additional contacts throughout
the hydrophobic cavity, involving in particular the MD-2 residues
I32, L78, Y102, F119, F121, K122, F126, and F151, which surround
the ligand andmediate the strongest van derWaals interactions within
the complex. In contrast to neoseptin, which is only able to activate
mouse TLR4/MD-2, cell-based assays show that L5 is active on both
human and mouse proteins, probably as a result of the extensive
hydrophobic network, which is conserved across species.
However, no strong hydrogen bonds or ionic interactions between L5
and TLR4/MD-2 could be predicted, implying a lack of speciﬁcity in
binding. This is unusual for protein-ligand interactions and has to
date only been described for DNA-ligand stacking interactions.32
The high ﬂexibility of the L5 molecule may allow it to ﬁt well into
the hydrophobic binding pocket, mediating extensive hydrophobic
contacts within the complex.Whereas hydrogen bond formation pro-
vides binding speciﬁcity and rigidity in molecular interactions, we
cannot rule out that water molecules and counter ions may associate
with the cationic headgroup.33 Potential hydrogen bonds and polar
interactions are foreseen with neighboring residues from MD-2
(residues R90 and E92), TLR4 (R264), and at the dimer interface
with TLR4’ at S415’, Q436’, and E439’ (Figure 2; Table S1). Whereas
DOTAP binding to inactive MD-2 is nonspeciﬁc, binding to the
active form of MD-2 nevertheless seems to be possible according to
our docking predictions. However, DOTAP docks more than 10 Å
from residue F126 and more than 15 Å from the dimerization inter-
face when artiﬁcially associated to the active conformation of MD-2.
Together with the lack of afﬁnity of DOTAP for inactive MD-2, these
data suggest that DOTAP does not possess any of the features essen-
tial for TLR4 activity, which is in sharp contrast to L5.
Docking studies further suggest that the hydrophobic moiety of L4 is
sufﬁcient for binding within the MD-2 cavity and for establishing sta-
bilizing contacts with the F126 loop, which are required for receptor
activation.34 Increasing the degree of acylation of the tetra-amine
backbone (L5 and L6) promotes a more surface-exposed conforma-
tion of the lipidoids with additional hydrophobic and hydrophilic
contacts (Table S2). In particular, L6 is the only tested lipidoid that
is able to interact with TLR4 at the primary site as well as at the dimer
interface (Table S3). Indeed, the R264 residue of TLR4 serves as a
hydrogen bond donor to the carbonyl group of the acyl chain linked
to N3. The additional contacts made by L6 contribute to its enhanced
TLR4 activity, as compared to the less acylated lipidoids. All lipidoids
studied here share conserved interactions with E439’ at the TLR4
dimer interface. The docking poses and binding afﬁnities are in accor-
dance with the observed TLR4 activity in the cell-based assays.
Figure 2. Binding Mode of L5
(A) Graphical representation of L5 (yellow) binding to TLR4/MD-2with primary TLR4 (green), secondary TLR4 at the dimer interface denoted TLR4’ (cyan), andMD-2 (magenta). L5
and its closest protein contacts are shown as stickswith oxygen (red) and nitrogen (blue) atoms. (B) Close-up of L5 filling up the hydrophobic cavity ofMD-2 is shown: the solvent-
accessible pocket of MD-2 is represented as a semi-transparent pinkmesh. (C) Different ligand conformations predicted for TLR4/MD-2 binding are shown: DOTAP, L5, and the
species-specific antagonist lipid IVa as observed in complex with human MD-2 (PDB: 2E59); the potent agonist E. coli lipid A (PDB: 3FXI); and the species-specific agonist
neoseptin, as observed in complex with mouse TLR4/MD-2 (PDB: 5HG4). The dotted line represents the same position of the ligand in the MD-2 cavity (see also Figure S3).
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Cells
Besides induction of an inﬂammatory response, activation of the
adaptive immune system by the designed siRNA delivery systems
should also be avoided. Professional antigen-presenting cells (pAPCs)
are initiators of adaptive responses, and upon encounter with drug
delivery systems, they may prime cells of the adaptive immune system
by inducing differentiation from an immature to a mature cell type.35
First, to test whether lipidoids affect viability and induce maturation
of pAPCs, murine bone marrow (BM)-derived APCs were incubated
with L5. A noticeable decrease in the viability of BM-APCs occurred
upon treatment with L5 at concentrations above 10 mg/mL as
compared to the viability of BM-APCs incubated with solvent or
LPS alone (Figure 3A). Within the live-cell population, no difference
was observed in the percentage of cells with a dendritic-like pheno-
type, measured as CD11c and major histocompatibility complex
(MHC) class II double-positive cells. However, a concentration-
dependent increase in maturation was noted in case of L5 up to
10 mg/mL, which was measured as an increase in the percentage of
CD40+ cells (Figure 3B) and CD86+ cells (data not shown). Reduced
maturation at higher concentrations could be attributed to cytotox-
icity (Figure 3A). Thus, the tested lipidoids do not only activate the
TLR4 pathway but do also induce maturation of BM-APCs.
TLR4 Activation and pAPC Maturation Are Influenced by the
Type of Formulation
The inﬂuence of formulation type on the immune-modulating
properties of lipidoids was subsequently assessed systematically bymeasuring TLR4 activation upon incubation with three different
types of formulations of lipidoids, viz. lipoplexes, SNALPs, and
LPNs. Lipoplexes represent the simplest type of formulation, and
they were prepared by simple co-incubation of siRNA and lipidoids
at a ﬁxed ratio of 1:20 (w/w). A concentration-dependent increase
in the relative TLR4 activation was measured for all types of lipo-
plexes, composed of L4, L5, and L6, respectively (Figure 4A). In case
of lipoplexes containing Lmix, a decrease in TLR4 activation was noted
at the highest concentration of 27 nM, as compared to that measured
at 2.7 nM, which could be attributed to the interference with the mea-
surement of TLR4 activation associated with toxicity (data not
shown). Furthermore, the pAPC maturation assay revealed that all
tested lipoplexes were well tolerated till 2.7 nM, albeit signiﬁcant
maturation was noted in all cases at the highest concentration of
27 nM (Figure 4B). Interestingly, remarkably higher pAPC matura-
tion was observed after incubation with bulk lipidoids (Figure 3B)
compared to incubation with lipoplexes, suggesting an inﬂuence
of siRNA complexation on the immune-stimulating properties of
lipidoids.
In addition, SNALPs formulated with L5 and Lmix, respectively, were
prepared as described previously (Table S4).10 Both L5 SNALPs and
Lmix SNALPs induced concentration-dependent TLR4 activation
from 2.5 nM till 27 nM, beyond which a decrease in TLR4 activation
was noted for both formulations (Figure 4C). This decrease can be
attributed to the interference with the measurement of TLR4 activa-
tion (data not shown). Like lipoplexes, both types of SNALPs induced
signiﬁcantly higher pAPC maturation at concentrations aboveMolecular Therapy: Nucleic Acids Vol. 11 June 2018 163
Figure 3. Lipidoid-Induced Cell Maturation Was Tested by Stimulating
Murine Bone-Marrow-Derived pAPCs Differentiated with Granulocyte
Macrophage Colony-Stimulating Factor
(A) Cell viability is shown as the percentage of cells in the live gate quantified by flow
cytometry upon stimulation with indicated concentrations of L5 and compared to
the viability of BM-APCs incubated with LPS and PBS. (B) Maturation is shown,
measured as the upregulation of the activation marker CD40 in CD11c+MHCII+
cells, and compared to CD40 levels on LPS (10 ng/mL) and PBS (1:25) incubated
BM-APCs. Data represent mean values ± SE (n = 2; technical replicates) and
represent results of one of a total of two independent experiments.
Molecular Therapy: Nucleic Acids2.7 nM, measured as the upregulation of the maturation marker
CD86 on BM-APCs (Figure 4D).
Finally, a series of siRNA-loaded LPNs was prepared with lipidoids
(L4, L5, and L6) and DOTAP as previously described (Table S4).
22
No TLR4 activation could be measured for LPNs modiﬁed with the164 Molecular Therapy: Nucleic Acids Vol. 11 June 2018lipidoids up to 100 nM siRNA (Figure 4E), independently of the
speciﬁc type of lipidoid used. Furthermore, LPNsmodiﬁed with either
lipidoid or DOTAP did not induce any upregulation of the matura-
tion markers CD86 (Figure 4F), CD40, and MHCII (data not shown),
indicating that they do not induce pAPC maturation (Figure 4F).
Interestingly, the LPNs did not inﬂuence the viability of BM-APCs
(Figure S2). Thus, as LPNs do not have any measurable immune-acti-
vating properties in the present studies, the LPN-based formulation
approach may be a promising delivery technology for further devel-
opment of siRNA-based therapies.
DISCUSSION
In previous studies we showed that both DOTAP-modiﬁed36 and in
particular lipidoid-modiﬁed LPNs are promising delivery systems for
siRNA, with an effective silencing of gene expression in cellular sys-
tems.22 However, to date very few studies have addressed the
potential undesired immune activation mediated by siRNA delivery
systems. In the present study, the immune-modulatory effects of newer
generation cationic lipids, i.e., lipidoids and various formulations
composed of lipidoids, were tested. The results clearly demonstrate
that bulk lipidoids are able to speciﬁcally activate TLR4, inducing a
pro-inﬂammatory environment, in contrast to the commonly used
cationic lipid DOTAP. However, formulation as lipidoid-modiﬁed
LPN substantially diminishes the lipidoid-mediated TLR4 activation.
In agreement with the measured TLR4 activation by the lipidoids
in vitro, we found that L4, L5, and L6 ﬁtted into the MD-2 groove
when analyzing possible binding to TLR4/MD-2 in silico. Whereas
L5 may be the most potent compound for siRNA transfection, L6
appeared to be the most immune-reactive structure. This structure
dependency was expected because the most potent TLR4 activators
known to date are bacterial hexa-acylated LPS molecules. Penta-
acylated lipids, e.g., LPS from Rhodobacter sphaeroides,37 and
tetra-acylated ones, for example, lipid IVa and eritoran, are either
species-speciﬁc partial agonists or antagonists.38 Thus, lipidoids,
including L4–L6, may adopt a conformation suitable for binding
to MD2, which is a prerequisite for dimerization and activation of
TLR4.28,29 In contrast, DOTAP was not predicted to bind with
high speciﬁcity to MD-2 and does therefore not qualify either as
a TLR4 agonist or as an antagonist, based on the in silico modeling.
Taken together, the in silico predictions correlate well with the
measured TLR4-activating abilities of the different test substances.
Thus, in silico modeling of structures seems to be useful to investi-
gate the potential of lipid structures for TLR4 binding during early
immunogenicity risk assessment.
Our comparison of the different types of L5-containing delivery sys-
tems (lipoplexes, SNALPs, and LPNs) with respect to TLR4 activation
in vitro shows that lipoplexes and SNALPs activate TLR4, whereas
formulation of L5 in LPNs reduces or even prevents lipidoid-mediated
TLR4 activation. Thus, the in vitro data suggest that LPNs may pro-
vide a non-immunogenic modality for intracellular siRNA delivery at
optimal dosing (see discussion below). L5-containing SNALPs are
currently being developed for antiviral therapy.15,39,40 This
Figure 4. Immune Activation by Lipidoid-Based SNALPs and Lipoplex and Not by Lipidoid-Modified LPNs
(A and B) Activation of the hTLR4 receptor cell line (A) and pAPC maturation (B) by lipoplexes composed of L4, L5, L6, or Lmix with siRNA-EGFP. (C and D) Activation of the
hTLR4 receptor cell line (C) and pAPCmaturation (D) by SNALPs prepared with L5 and Lmix, respectively, is shown. (E and F) Activation of the hTLR4 receptor cell line (E) and
pAPC maturation (F) induced by LPNs prepared with L4, L5, L6, Lmix, or DOTAP is shown. Sample OD was corrected for OD value measured for the negative control (solvent
1:10) and divided by the maximum OD (LPS 10 ng/mL). Professional APC maturation was tested by stimulating murine bone-marrow-derived, granulocyte macrophage
colony-stimulating factor (GM-CSF)-differentiated pAPCs. Maturation was measured as the upregulation of the activation marker CD86 in CD11c+MHCII+ cells
and compared to the levels on BM-APCs stimulated with LPS (10 ng/mL) and PBS, as quantified by flow cytometry (see also Figure S2). Data represent mean values ± SD
(n = 3 for A, C, and E and n = 2 for B, D, and F technical replicates).
www.moleculartherapy.orgdifferential activation of TLR4 may be explained by important differ-
ences in the physicochemical characteristics of the delivery systems.
These include the way the lipidoid molecules are exposed on the sur-
face of the nanoparticles and how the lipidoid-containing structures
are presented to the receptor.41 Because SNALPs and LPNs are
composed of different materials, the structure of the particles differs
for the two particle types and, most likely, therefore also the way L5 is
exposed on the particle surface. In addition, we hypothesize that LPS-
binding protein (LBP), which is capable of extracting LPS from
bacterial membranes,42,43 may be able to access and bind lipidoid
molecules present in the looser packed membrane bilayers of
SNALPs, but not the lipidoid molecules of the more tightly packed
shell membrane structure that we suggest coats the PLGA core of
LPNs.44 As a consequence, the L5 component of the particles mayinteract differently with the MD-2/TLR4 molecules, depending on
the speciﬁc particle structure. Further studies are needed to test this
hypothesis.45
Although lipidoid-induced TLR4 activation represents a potential
safety concern, formulating lipidoids into LPN structures appears
to modulate lipidoid-mediated TLR4 activation in a beneﬁcial direc-
tion. This suggests that lipidoid-containing LPNs may be a promising
platform technology for siRNA delivery. Of particular importance is
that a concentration of 2.6 nM siRNA delivered with L5-modiﬁed
LPNs induced 50% gene silencing (inhibitory concentration
50 [IC50]) after 24 hr:
22 at this time point (16–24 hr), we could not
measure any detectable immune activation by the LPNs at siRNA
concentrations as high as 100 nM. This indicates that cellular eventsMolecular Therapy: Nucleic Acids Vol. 11 June 2018 165
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ing place during this time interval do apparently not result in expo-
sure of L5 to TLR4. In contrast, SNALPs and lipoplexes activate
TLR4 already at concentrations corresponding to 2.6 nM siRNA.
These types of delivery systems mediate less efﬁcient gene silencing
than LPNs (IC50 values of 5.6 and 25.5 nM, respectively).
22 Our pre-
viously reported in vitro gene silencing data and the present in vitro
immunogenicity data thus suggest that the LPNs are the most prom-
ising of the tested siRNA delivery technologies. However, further
studies are needed to investigate the effect of LPNs on immunoge-
nicity at higher doses and longer exposure times. In addition, preclin-
ical in vivo safety and efﬁcacy studies are needed to investigate
whether there is a correlation between these early immunogenicity
risk assessment ﬁndings in silico and in vitro and the in vivo situation.
A few studies reported in the literature have investigated potential im-
mune-activating effects of cationic lipid nanoparticles. Of particular
interest is that, whereas bulk DOTAP and DOTAP-containing
LPNs did not induce any immune activation in the present in vitro
studies, DOTAP-containing liposomes did stimulate release of pro-
inﬂammatory cytokines after in vivo administration in mice.46 This
apparent difference may be attributed to the composition of the
lipid-based nanoparticles: in contrast to the LPNs examined in the
present study, the DOTAP-containing nanoparticles tested in the
referred in vivo studies did also contain cholesterol and phosphatidyl-
choline, which may contribute to induction of an inﬂammatory
response.47 In addition, species-speciﬁc differences in TLR4 activa-
tion (mouse versus human) may also inﬂuence the results.
We envisage that the differences in innate immune activation
measured in the present study may be more actively exploited in
the ﬁeld of advanced drug delivery systems for nucleic-acid-based
drugs. If the aim is to deliver an antiviral or an anticancer drug, spe-
ciﬁc immune activation may be a desirable outcome. The immune-
stimulating effects of unmodiﬁed RNA in combination with SNALPs
have already been described in the literature, and these effects likely
contribute to efﬁcacious antiviral therapy;38,39 TLR4 activation medi-
ated by the lipidoid component of SNALPs may contribute to that. In
conclusion, the different possibilities we have with respect to design of
drug delivery systems may provide a range of opportunities for
customizing the formulations toward speciﬁc, desirable outcomes.
MATERIALS AND METHODS
Materials
20-O-methyl-modiﬁed dicer substrate asymmetric siRNA duplexes
directed against EGFP (EGFP-siRNA) and scrambled negative
control siRNA were synthesized by GlaxoSmithKline (Stevenage,
UK) and provided generously as dried, puriﬁed, and desalted
duplexes (Table S5). The siRNA stock solutions were prepared in
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer
(5 mM; pH 7.4) and re-annealed employing a standard protocol
recommended by IDT (Coralville, IA, USA). PLGA with a lactide-
to-glycolide molar ratio of 75:25 and a molecular weight of 20 kDa
was procured from Wako Pure Chemical Industries (Osaka, JP).166 Molecular Therapy: Nucleic Acids Vol. 11 June 2018Polyvinyl alcohol (PVA) 403 with an 80.0% degree of hydrolysis
was purchased from Kuraray (Osaka, JP). Cholesterol, DOTAP,
and N-palmitoyl-sphingosine-1-succinyl[methoxy(polyethylene gly-
col)2000] (C16 PEG2000 ceramide) were obtained from Avanti Polar
Lipids (Alabaster, AL, USA). Heparin, octyl-b-d-glucopyranoside
(OG), and Tris–EDTA buffer (10 mM Tris and 1 mM EDTA [pH
7.5], referred to as TE buffer) were purchased from Sigma-Aldrich
(St. Louis, MO, USA). RNase-free diethyl pyrocarbonate (DEPC)-
treated Milli-Q water was used for all buffers and dilutions. All other
chemicals, unless otherwise stated, were of analytical grade and ob-
tained from local suppliers.
Preparation of Lipoplexes
The array of lipidoids was synthesized, puriﬁed, and characterized as
previously described.22 Lipoplexes were prepared by co-incubation of
the lipidoids (L4, L5, L6, and Lmix) and EGFP-siRNA. A stock solution
(40 mg/mL) of the respective lipidoid was prepared by dissolving it in
DMSO containing 1% (v/v) triﬂuoroacetic acid. Lipoplexes were pre-
pared by addition of the stock solution to a siRNA solution in TE
buffer at a lipidoid:siRNA ratio of 1:20 (w/w). The lipoplexes were
vigorously vortexed before use. For Lmix, the molecular weight of L5
was assumed for molarity calculations.
Preparation of SNALPs
Lipidoid-based SNALPs were prepared as reference formulation for
comparative purpose. A previously reported ethanol destabilization
method10 was adopted22 and employed for preparation of L5-
modiﬁed SNALPs and Lmix-modiﬁed SNALPs. Brieﬂy, an in situ
buffer formation technique was used to formulate lipidoid-based
SNALPs, considering its low solubility in EtOH. The lipidoid, choles-
terol, and C16 PEG2000 ceramide were dissolved in EtOH at molar
ratio of 42:48:10 using glacial acetic acid, and the mixture was added
to an aqueous solution of NaOAc, resulting into formation of non-
loaded SNALPs. The SNALPs were prepared at a lipid concentration
of 10 mg/mL and loaded with EGFP-siRNA at a siRNA:lipid loading
ratio of 1:7.5 (w/w) at 37C for 30 min. The siRNA-loaded
SNALPs were dialyzed against 1,000 volume PBS (pH 7.4) using a
100 kDa molecular weight cutoff dialysis membrane cassette (Float-
A-Lyzer, G2; Spectrum Laboratories, Rancho Dominguez, CA, US)
for 2 hr at room temperature to remove excess EtOH and un-
entrapped siRNA. The detailed protocol for the preparation of
SNALPs has been reported elsewhere.22
Preparation of LPNs
Lipidoid- and DOTAP-modiﬁed LPNs were prepared by using the
double emulsion solvent evaporation method, as reported previ-
ously,48 but with a slight modiﬁcation.22 Brieﬂy, an aqueous phase
(w1) comprising the required amount of EGFP-siRNA in 125 mL
HEPES buffer (5 mM; pH 7.4) was added to an organic phase
(o; 250 mL CH2Cl2) containing PLGA and lipidoid or DOTAP. The
formed primary emulsion was subjected to probe sonication at an
amplitude of 50 (Misonix; Qsonica, CT, USA) in an ice bath. The
primary w1/o emulsion was phase inversed by addition of 1 mL of
2% (w/v) PVA solution and vigorous vortexing for 1 min. The formed
www.moleculartherapy.orgsecondary w1/o/w2 double emulsion was subsequently subjected to
probe sonication at an amplitude of 50 for additional 60 s. The
size-reduced emulsion was transferred to a 25-mL beaker, and
5mL of 2% (w/v) PVA solution was added under stirring. The stirring
was continued for 45 min to facilitate the evaporation of the organic
solvent. The prepared LPNs were then washed, puriﬁed, and lyophi-
lized as reported previously.22 The lipidoid-modiﬁed LPNs were pre-
pared at a lipidoid content of 15% (w/w) of the total solid content,
whereas DOTAP-modiﬁed LPNs were prepared at 10% (w/w).
Furthermore, the siRNA:lipidoid weight ratio was kept constant at
1:20 in case of lipidoid-modiﬁed LPNs, whereas it was 1:10 (w/w)
for the DOTAP-modiﬁed LPNs.
Physicochemical Characterization
The formulations were characterized with respect to hydrodynamic
diameter, polydispersity index (PDI), zeta potential, and siRNA
entrapment efﬁciency as previously described.22
In brief, a dynamic light scattering technique employing photon cor-
relation spectroscopy (Zetasizer Nano ZS; Malvern Instruments,
Worcestershire, UK) was used to measure the particle size and PDI
of the formulations. Furthermore, the same samples were also used
to measure the zeta potential employing the principles of laser
Doppler micro-electrophoresis. The data for three independent
batches were recorded and analyzed using the Zetasizer Software
version 7.11 (Malvern Instruments).
The siRNA entrapment efﬁciency of LPNs and SNALPs was evaluated
using a previously reported procedure.22,48 Brieﬂy, siRNA was
extracted from the formulations by high-speed centrifugation and
resuspension in CHCl3, and 100 mM OG and heparin were added
to efﬁciently extract siRNA. Subsequently, after centrifugation,
siRNA was quantiﬁed in the aqueous phase of the solution using
the Quant-iT RiboGreen RNA Assay Kit (Molecular Probes, Invitro-
gen, Paisley, UK) according to the manufacturer’s protocol. The
encapsulation efﬁciency and practical loading were calculated using
the following equations:
Encapsulation efficiency =
Amount of entrapped siRNA
Total amount of added siRNA
 100
(Equation 1)
Practical loading =
Amount of entrapped siRNA
Total weight of nanoparticles
 100:
(Equation 2)
Toll-like Receptor Activation Assays
The human TLR reporter cell lines (HEK-BluehTLR2, -hTLR3,
-hTLR4, -hTLR7, and -hTLR9 reporter cells) were cultured according
to the manufacturer’s instructions (Invivogen, Toulouse, FR). Activa-
tion of hTLRs was measured according to the previously reported
protocol.49 In brief, the reporter cell line assays were performed in
serum-containing cell culture medium. Cells were seeded in ﬂat96-well plates and stimulated with different dilutions of fully
dispersed lipids, lipoplexes, LPNs, and SNALPs, respectively, for
16 hr at 37C, after which the cell culture supernatants were incubated
with protein substrate QUANTIBlue (Invivogen) for 1 hr. Absorption
was measured using a microplate reader (Bio-Rad 550; Bio-Rad, CA,
USA) at optical density 650 (OD650) nm. The control value (solvent
incubated) was subtracted from sample value. The relative alkaline
phosphatase levels were then deﬁned relative to the maximum TLR
activation by the corresponding agonist.
BM-APC Differentiation and APC Maturation Assays
Murine BM-APCs were differentiated with GM-CSF and cultured ac-
cording to a reported protocol.49 Brieﬂy, BM-APCs were stimulated
with PBS (1:100 or 1:25; v/v), LPS (O127:B8; 10 ng/mL; Sigma-
Aldrich, MO, USA), or with a concentration series of fully dispersed
lipids, lipoplexes, LPNs, or SNALPs, respectively, for 16 hr at 37C.
Maturation was measured by antibody staining of the maturation
markers CD40 and CD86, and the samples were analyzed using
ﬂow cytometry. Ethical approval for the mouse experiment was
obtained from the Animal Experiment Committee of Utrecht
University, the Netherlands, no. DEC.2013.II.09.102.
Molecular Modeling Studies
The atomic coordinates of DOTAP and L4, L5, and L6 lipidoids were
generated using the Sybyl software, a general molecular modeling
program from Tripos, for which a partial license was donated to
the Department of Biochemistry, University of Cambridge, UK.50
Brieﬂy, Sybyl’s sketching tool was used to build the molecules, fol-
lowed by a clean-up, which performs rough dynamics. Constraints
were applied to bond lengths, angles, and torsions. The geometry of
the molecules was optimized using the Powell minimization method
with initial optimization based on the Simplex method, with a
gradient of 0.05 kcal/mol and a maximum of 100 cycles of iteration.
Partial charges were computed based on the Gasteiger-Hückel charge
method using calculator plugin of Marvin Suite (version 17.2.20;
ChemAxon, Budapest, Hungary).51 AutoDockTools452 was used to
convert the atomic coordinate ﬁles into a PDB partial charge, Q,
and atom type, T, (PDBQT) format that contains the partial
charges and atom types of the molecules, in addition to the atomic
coordinates.52
For docking studies, the human crystal structures of lymphocyte an-
tigen 96 (also known as MD-2) in the absence and presence of TLR4
(PDB: 2E59 and PDB: 3FXI, respectively) were used for docking upon
removal of the ligands bound to the protein complexes. The potential
ligands (DOTAP and L5) were docked into MD-2 using Autodock
Vina.27 The protein component was kept rigid, whereas the ligand
was allowed full ﬂexibility. The Autogrid parameters were computed
on an initial grid size of 32  32  32 Å3, with a spacing of 1 Å. The
grid was centered on MD-2 at x = +22.626; y = 9.61; z = +15.271.
The default optimization parameters were used for the iterated search
in Vina, with a value of 32 for exhaustiveness. Flexible docking
performed with DOTAP and lipidoid ligands generated a number
of poses, ranked according to their binding energies. The highestMolecular Therapy: Nucleic Acids Vol. 11 June 2018 167
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Vina algorithm were then subjected to rigid docking in order to
compare the binding afﬁnity of molecules of different sizes. The
conformation of the docked ligands and their contacts with MD-2
and TLR4, where appropriate, were analyzed using PISA.53 Structural
images were generated in PyMol (https://pymol.org/2) and
Chimera.54 Detailed interactions were also analyzed using LigPlot+.55
Control docking experiments were performed on ligands with known
crystal structures to compare their binding energies to lipidoids and
DOTAP molecules. Controls included a potent TLR4/MD-2 agonist:
the lipid A moiety of Escherichia coli LPS,29 a species-speciﬁc antag-
onist: lipid Iva,28 and a potent antagonist: eritoran.30 Rigid docking of
these control ligands provided the binding energies that directly
related to the experimental conformations adopted by these
molecules.
Statistics
Results are expressed as mean values ± SD. Statistical analysis was
performed using GraphPad Prism (GraphPad, La Jolla, CA, USA).
Statistically signiﬁcant differences were assessed by ANOVA followed
by aDunnett’smultiple comparison test; p value below 0.05was consid-
ered statistically signiﬁcant. Signiﬁcance of the results is indicated
according to p values (*p < 0.05, **p < 0.01, and ***p < 0.001). A p value
below 0.05 was considered statistically signiﬁcant.
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